ETS-related Gene mRNA May Be Useful Test for Prostate Cancer(3/15/2010) Two clinical studies presented at the 2010 Genitourinary Cancer Symposium suggest that a ETS-related gene mRNA urine test (TMPRSS2-ERG or T2ERG) may be useful in diagnosing prostate cancer and predicting the results of prostate biopsies.
Urinary Prostate Cancer Test, PCA3, Predictive of Biopsy Outcomes(3/9/2010) Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium held in San Francisco, March 5-7.
MRI-guided Prostate Biopsies Useful for Men with Repeat Negative Biopsies(1/12/2010) Researcher from the Netherlands have reported that magnetic resonance imaging (MRI)-guided prostate biopsy is an effective technique in men who have had repeat negative biopsies despite an elevated prostate specific antigen (PSA) level. The details of this study appeared in the February 2010 issue of the Journal of Urology.
Coffee May Reduce Risk of Lethal and Advanced Prostate Cancer(12/21/2009) Researchers affiliated with the Health Professionals’ Follow-up Study have reported that men who drink coffee may have a reduced risk of developing lethal and advanced prostate cancer. These results were presented at the 2009 AACR Frontiers in Cancer Prevention Research conference.
Disagreement over USPSTF Recommendation to Discontinue PSA Screening in Men at Age 75(11/25/2009) Researchers from Duke University have concluded that 78% of men 75 years of age or older disagree with the recommendations of the U.S. Preventative Task Force (USPSTF) to not screen with prostate-specific antigen (PSA) for prostate cancer. They also pointed out that men aged >/= 75 years had higher risk disease and poorer survival than younger men. The details of this study were published early online in Urology on October 6, 2009.
Neoadjuvant Taxotere® and Emcyt® for High-risk Localized Prostate Cancer Is Tolerable(3/15/2010) Researchers from France have reported preliminary results of a Phase III randomized trial of neoadjuvant Taxotere® (docetaxel), Emcyt® (estramustine), and Zoladex® (goserelin) versus goserelin alone in men with high-risk prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco, March 5 to 7.
Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer(3/12/2010) Researchers affiliated with the RTOG 94-08 clinical trial have reported that short-term androgen deprivation therapy (ADT) delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco on March 5-7.
Gene Signature Test May Help Predict Recurrences of Prostate Cancer After Prostatectomy(3/8/2010) Researchers from the University of Texas at San Antonio, the University of Utah, and Myriad Genetics, Inc. have reported that a gene signature test performed on prostate cancer tissue can help predict the probability of recurrent disease in men with localized prostate cancer treated with radical prostatectomy. The details of this study were presented at the 2010 meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.
Long-term Results Confirm Benefit of High-dose Conformal Radiation for Early-stage Prostate Cancer(3/4/2010) Researchers affiliated with the Proton Radiation Oncology Group/American College of Radiology 95-09 study have concluded that high-dose conformal radiation therapy results in better long-term cancer control than conventional-dose radiation therapy for treatment of localized prostate cancer. The details of this follow-up study were published in the March, 2010 issue of the Journal of Clinical Oncology.
Laparoscopic Prostatectomy and Open Prostatectomy Have Similar Rates of Complications(3/2/2010) Researchers from the Sidney Kimmel Cancer Center and the Memorial Sloan-Kettering Cancer Center have reported that men treated with laparoscopic prostatectomy have similar rates of postoperative complications to men undergoing open prostatectomy. The details of this population-based study were published early online on February 24, 2010 in the Journal of Urology.
Laparoscopic Prostatectomy and Open Prostatectomy Have Similar Rates of Complications(3/2/2010) Researchers from the Sidney Kimmel Cancer Center and the Memorial Sloan-Kettering Cancer Center have reported that men treated with laparoscopic prostatectomy have similar rates of postoperative complications to men undergoing open prostatectomy. The details of this population-based study were published early online on February 24, 2010 in the Journal of Urology.
Adjuvant Taxol® and ADT Well Tolerated in Men with High-risk Prostate Cancer(2/12/2010) Researchers from France have reported that a regimen of adjuvant Taxol® (paclitaxel) and androgen deprivation therapy (ADT) was well tolerated after radical prostatectomy for men with high-risk prostate cancer. The details of this study were published in the March, 2010 issue of Prostate Cancer and Prostatic Diseases.
Quality of Life of Prostate Cancer Patients Differs by Treatment Choice(2/9/2010) Researchers from Australia have reported that various treatments for prostate cancer have “persistent effects on quality of life.” The details of this population-based cohort study were published in the January 23, 2010 issue of the British Journal of Medicine.
Many Low-volume Surgeons Performing Prostatectomies in the US(1/12/2010) Researchers from Memorial Sloan-Kettering Cancer Center have reported that 80% of U.S. surgeons perform fewer that 10 radical prostatectomies per year and 25% perform only one per year. The details of this study appeared in the December 2009 issue of the Journal of Urology.
Denosumab May Be Superior to Zometa® for Treatment of Bone Metastases in Men with Metastatic Prostate Cancer(2/10/2010) An Amgen press release has reported that a randomized Phase III trial comparing denosumab to Zometa® (zoledronic acid) in men with bone metastases from prostate cancer has been completed. This study showed that denosumab was more effective than Zometa in delaying time to first on-study skeletal related event (SRE) and reducing the rate of multiple SREs.
Vaccine May Improve Survival of Patients with Metastatic Castration-resistant Prostate Cancer(2/9/2010) Researchers from the Dana-Farber Cancer Institute, the University of Colorado, and the National Cancer Institute have reported that the vaccine PROSTAC-VF (PROSTVAC®-VF/TRICOM™) plus granulocyte macrophage-colony stimulating factor (GM-CSF) may improve survival of patients with metastatic castration-resistant prostate cancer. The details of this study appeared in an early online publication in the Journal of Clinical Oncology (JCO) on January 25, 2010.
Sprycel® May Have Activity for Treating Castration-resistant Prostate Cancer(12/3/2009) Researchers from Italy have reported that Sprycel® (dasatinib) may have significant activity for treating patients with castration-resistant prostate cancer (CRPC) with bone metastases. The details of this Phase II study were published in the December 1, 2009 issue of Clinical Cancer Research.
Radium-223 (Alpharadin®) Effective Palliation for Prostate Cancer Metastatic to Bone(10/9/2009) Researchers involved in three Phase II European multicenter studies have reported that Alpharadin® (radium-223), an alpha emitter, is effective and well tolerated for the treatment of men with hormone refractory prostate cancer (HRPC) with metastatic bone lesions. The details of these studies were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24 2009.
Radiotherapy plus Adjuvant Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Ten-year Results(10/8/2009) Researchers affiliated with European Organization for Research for the Treatment of Cancer (EORTC) trial 22863 have reported that three years of adjuvant androgen deprivation therapy (ADT) in men with locally advanced prostate cancer receiving radiotherapy improves survival without late cardiovascular toxicity with a 10-year follow-up. The details of this analysis were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Updated Survival Data on Provenge® for Treatment of Hormone Refractory Prostate Cancer Presented(3/11/2010) Researchers affiliated with the IMPACT trial have reported that additional follow-up and more analyses demonstrate a clear survival advantage of Provenge® (sipuleucel-T) versus placebo in men with hormone-refractory prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco between March 5 and 7.
Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere®(3/5/2010) Researchers involved in the multicenter international Phase III trial (TROPIC) have reported that cabazitaxel (XRP-6258) was superior to Novantrone® (mitoxantrone) for the treatment of patients with hormone refractory prostate cancer (HRPC) who had failed treatment with Taxotere® (docetaxel). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.
Abiraterone, an Inhibitor of Cytochrome P17, Confirmed Effective in Hormone Refractory Prostate Cancer(3/3/2010) Three studies published early online in the Journal of Clinical Oncology on February 16, 2010 have confirmed that abiraterone acetate, an inhibitor of cytochrome P17, is active in men with hormone refractory prostate cancer (HRPC). These studies also suggest that patients who cease to respond to current androgen depravation therapy (ADT) will respond to an alternative form of androgen deprivation.
Sprycel® May Have Activity for Treating Castration-resistant Prostate Cancer(12/3/2009) Researchers from Italy have reported that Sprycel® (dasatinib) may have significant activity for treating patients with castration-resistant prostate cancer (CRPC) with bone metastases. The details of this Phase II study were published in the December 1, 2009 issue of Clinical Cancer Research.
New Oral Agent, Tasquinimod, May Have Activity in Prostate Cancer(10/26/2009) Researchers from Sweden have reported that tasquinimod, an oral analog of linomide, may have significant activity in men with hormone-refractory prostate cancer (HRPC). The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.
Patient Home
